These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20926375)

  • 1. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.
    Loveridge C; Tonelli F; Leclercq T; Lim KG; Long JS; Berdyshev E; Tate RJ; Natarajan V; Pitson SM; Pyne NJ; Pyne S
    J Biol Chem; 2010 Dec; 285(50):38841-52. PubMed ID: 20926375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
    McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
    Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b.
    Lim KG; Tonelli F; Berdyshev E; Gorshkova I; Leclercq T; Pitson SM; Bittman R; Pyne S; Pyne NJ
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1457-64. PubMed ID: 22634604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
    Tonelli F; Lim KG; Loveridge C; Long J; Pitson SM; Tigyi G; Bittman R; Pyne S; Pyne NJ
    Cell Signal; 2010 Oct; 22(10):1536-42. PubMed ID: 20570726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.
    Tonelli F; Alossaimi M; Williamson L; Tate RJ; Watson DG; Chan E; Bittman R; Pyne NJ; Pyne S
    Br J Pharmacol; 2013 Mar; 168(6):1497-505. PubMed ID: 23113536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells.
    Watson DG; Tonelli F; Alossaimi M; Williamson L; Chan E; Gorshkova I; Berdyshev E; Bittman R; Pyne NJ; Pyne S
    Cell Signal; 2013 Apr; 25(4):1011-7. PubMed ID: 23314175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roles of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells.
    Tonelli F; Alossaimi M; Natarajan V; Gorshkova I; Berdyshev E; Bittman R; Watson DG; Pyne S; Pyne NJ
    Biomolecules; 2013 Jun; 3(2):316-33. PubMed ID: 24970170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P
    Alganga H; Almabrouk TAM; Katwan OJ; Daly CJ; Pyne S; Pyne NJ; Kennedy S
    J Pharmacol Exp Ther; 2019 Oct; 371(1):63-74. PubMed ID: 31371480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation.
    Ren S; Xin C; Pfeilschifter J; Huwiler A
    Cell Physiol Biochem; 2010; 26(1):97-104. PubMed ID: 20502009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells.
    Lim KG; Tonelli F; Li Z; Lu X; Bittman R; Pyne S; Pyne NJ
    J Biol Chem; 2011 May; 286(21):18633-40. PubMed ID: 21464128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.
    Powell JA; Pitman MR; Zebol JR; Moretti PAB; Neubauer HA; Davies LT; Lewis AC; Dagley LF; Webb AI; Costabile M; Pitson SM
    Biochem J; 2019 Nov; 476(21):3211-3226. PubMed ID: 31652307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer.
    Ohotski J; Long JS; Orange C; Elsberger B; Mallon E; Doughty J; Pyne S; Pyne NJ; Edwards J
    Br J Cancer; 2012 Apr; 106(8):1453-9. PubMed ID: 22460268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells.
    Leroux ME; Auzenne E; Evans R; Hail N; Spohn W; Ghosh SC; Farquhar D; McDonnell T; Klostergaard J
    Prostate; 2007 Nov; 67(15):1699-717. PubMed ID: 17879964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells.
    Long JS; Edwards J; Watson C; Tovey S; Mair KM; Schiff R; Natarajan V; Pyne NJ; Pyne S
    Mol Cell Biol; 2010 Aug; 30(15):3827-41. PubMed ID: 20516217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.
    Evangelisti C; Evangelisti C; Teti G; Chiarini F; Falconi M; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Beak DJ; Bittman R; Pyne S; Pyne NJ; Martelli AM
    Oncotarget; 2014 Sep; 5(17):7886-901. PubMed ID: 25226616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of selective inhibitors of sphingosine kinase 1.
    Baek DJ; MacRitchie N; Pyne NJ; Pyne S; Bittman R
    Chem Commun (Camb); 2013 Mar; 49(21):2136-8. PubMed ID: 23388656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53.
    Taha TA; Osta W; Kozhaya L; Bielawski J; Johnson KR; Gillanders WE; Dbaibo GS; Hannun YA; Obeid LM
    J Biol Chem; 2004 May; 279(19):20546-54. PubMed ID: 14988393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.
    Antoon JW; White MD; Burow ME; Beckman BS
    Oncol Rep; 2012 Jun; 27(6):1779-86. PubMed ID: 22469881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.
    Truman JP; Ruiz CF; Trayssac M; Mao C; Hannun YA; Obeid LM
    FASEB J; 2021 Feb; 35(2):e21284. PubMed ID: 33484475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of sphingosine kinase 1 enhances cytotoxicity, ceramide levels and ROS formation in liver cancer cells treated with selenite.
    Chatzakos V; Rundlöf AK; Ahmed D; de Verdier PJ; Flygare J
    Biochem Pharmacol; 2012 Sep; 84(5):712-21. PubMed ID: 22727936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.